Mental health care for all, no prescription necessary
Our digital therapeutics are safe and effective non-drug alternatives for mental health.*
Most people in need of mental health care don’t receive it
For those who are able to get care, 82% are given medication – but medication isn’t always the best option.1
Our digital therapeutics deliver effective help with no serious side effects
Daylight and Sleepio are easily accessible, safe, and highly effective.6,7
Trusted by the world’s leading organizations
For nearly a decade, we’ve been empowering employers and health plans
to help millions back to good mental health.
Simple to adopt,
The easiest way to offer non-drug alternatives to members of your population in need.
Add coverage to your
Pre-approved by major pharmacy benefit managers, add coverage in as few as 10 days.
Offer access via
existing care pathways
Easily reach members at the time of need.
Bill via pharmacy invoice
Deep integrations mean you get to bill for therapeutic use via your pharmacy invoice.
We believe evidence
is a duty, not a chore
We’re committed to gold-standard clinical evidence. We have 64 publications with more than 28,000 participants, including 13 randomized controlled trials (RCTs).
of patients achieved clinical improvement in anxiety.6
of patients achieved clinical improvement in insomnia.7
Here’s our latest
Integrate digital therapeutics into the pharmacy pathway
Effective mental health care via your PBM, faster and easier than ever.
Bringing employee mental health into focus — Part 3
Yes, employees need mental health literacy. Two clinical psychologists explain why.
Behavioral medicine: Preferred by employees, hard to scale for employers
Despite millions of people receiving mental health medications, most would prefer to receive behavioral care.
*Disclaimer: In accordance with FDA’s Current Enforcement Discretion Policy for Digital Health Devices for Psychiatric Disorders, for patients aged 18 years and older, who are followed by and diagnosed with Insomnia Disorder or Generalized Anxiety Disorder by a medical provider, Sleepio and Daylight can be made available as an adjunct to their usual medical care for Insomnia Disorder or Generalized Anxiety Disorder, respectively. Sleepio and Daylight do not replace the care of a medical provider or the patient’s medication. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for these indications. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.
1. Terlizzi, E. P., & Zablotsky, B. (2020). Mental Health Treatment Among Adults: United States, 2019. NCHS Data Brief, (380), 1-8.
2. Lembke, A., Papac, J., & Humphreys, K. (2018). Our other prescription drug problem. The New England journal of medicine, 378(8), 693-695.
3. Pillai, V., Roth, T., Roehrs, T., Moss, K., Peterson, E. L., & Drake, C. L. (2017). Effectiveness of benzodiazepine receptor agonists in the treatment of insomnia: an examination of response and remission rates. Sleep, 40(2), zsw044.
4. Rickels, K., & Rynn, M. (2002). Pharmacotherapy of generalized anxiety disorder. The Journal of clinical psychiatry, 63(suppl 14), 9-16.
5. McHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A., & Otto, M. W. (2013). Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. The Journal of clinical psychiatry, 74(6), 0-0.
6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and anxiety, 37(12), 1168-1178.
7. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.